<?xml version="1.0" encoding="utf-8" ?><rss version="2.0"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:media="http://search.yahoo.com/mrss/">

   <channel>
       <title>2026 - NANETS</title>
       <description><![CDATA[]]></description>
       <link>https://nanets.net/abstracts-archive/2026?format=html</link>
              <lastBuildDate>Thu, 05 Nov 2026 06:00:00 -0500</lastBuildDate>
       <atom:link href="https://nanets.net/abstracts-archive/2026?format=rss" rel="self" type="application/rss+xml"/>
       <language>en-GB</language>
       <sy:updatePeriod>hourly</sy:updatePeriod>
       <sy:updateFrequency>1</sy:updateFrequency>

              <item>
           <title>[C31] Bisht - Recurrence of Locoregional Small Bowel Neuroendocrine Tumors Developing a Risk Prediction Nomogram</title>
           <link>https://nanets.net/abstracts-archive/2026/2276-c31-bisht-recurrence-of-locoregional-small-bowel-neuroendocrine-tumors-developing-a-risk-prediction-nomogram?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2276-c31-bisht-recurrence-of-locoregional-small-bowel-neuroendocrine-tumors-developing-a-risk-prediction-nomogram/file" length="116374" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2276-c31-bisht-recurrence-of-locoregional-small-bowel-neuroendocrine-tumors-developing-a-risk-prediction-nomogram/file"
                fileSize="116374"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[C31] Bisht - Recurrence of Locoregional Small Bowel Neuroendocrine Tumors Developing a Risk Prediction Nomogram</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2276-c31-bisht-recurrence-of-locoregional-small-bowel-neuroendocrine-tumors-developing-a-risk-prediction-nomogram?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Thu, 05 Nov 2026 06:00:00 -0500</pubDate>
       </item>
              <item>
           <title>[O19] El Sweilmein - Real World Trends in Telotristat Utilization for Carcinoid Syndrome in the United States A National Epic Cosmos Analysis</title>
           <link>https://nanets.net/abstracts-archive/2026/2301-o19-el-sweilmein-real-world-trends-in-telotristat-utilization-for-carcinoid-syndrome-in-the-united-states-a-national-epic-cosmos-analysis?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2301-o19-el-sweilmein-real-world-trends-in-telotristat-utilization-for-carcinoid-syndrome-in-the-united-states-a-national-epic-cosmos-analysis/file" length="94882" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2301-o19-el-sweilmein-real-world-trends-in-telotristat-utilization-for-carcinoid-syndrome-in-the-united-states-a-national-epic-cosmos-analysis/file"
                fileSize="94882"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[O19] El Sweilmein - Real World Trends in Telotristat Utilization for Carcinoid Syndrome in the United States A National Epic Cosmos Analysis</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2301-o19-el-sweilmein-real-world-trends-in-telotristat-utilization-for-carcinoid-syndrome-in-the-united-states-a-national-epic-cosmos-analysis?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Thu, 05 Nov 2026 04:08:30 -0500</pubDate>
       </item>
              <item>
           <title>[C18 Poster] Yoon - [177Lu]Lu edotreotide Effectiveness in Patients with Functional and Non functional Gastrointestinal Neuroendocrine Tumors A SwissNET Registry Analysis</title>
           <link>https://nanets.net/abstracts-archive/2026/2357-c18-poster-yoon-177lu-lu-edotreotide-effectiveness-in-patients-with-functional-and-non-functional-gastrointestinal-neuroendocrine-tumors-a-swissnet-registry-analysis?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2357-c18-poster-yoon-177lu-lu-edotreotide-effectiveness-in-patients-with-functional-and-non-functional-gastrointestinal-neuroendocrine-tumors-a-swissnet-registry-analysis/file" length="8247288" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2357-c18-poster-yoon-177lu-lu-edotreotide-effectiveness-in-patients-with-functional-and-non-functional-gastrointestinal-neuroendocrine-tumors-a-swissnet-registry-analysis/file"
                fileSize="8247288"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[C18 Poster] Yoon - [177Lu]Lu edotreotide Effectiveness in Patients with Functional and Non functional Gastrointestinal Neuroendocrine Tumors A SwissNET Registry Analysis</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2357-c18-poster-yoon-177lu-lu-edotreotide-effectiveness-in-patients-with-functional-and-non-functional-gastrointestinal-neuroendocrine-tumors-a-swissnet-registry-analysis?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:55:44 -0500</pubDate>
       </item>
              <item>
           <title>[O16 Poster] Pavel - Establishing content validity of patient reported outcome (PRO) measures in extrapulmonary neuroendocrine carcinomas (epNEC) A cognitive debriefing (CD) interview study</title>
           <link>https://nanets.net/abstracts-archive/2026/2356-o16-poster-pavel-establishing-content-validity-of-patient-reported-outcome-pro-measures-in-extrapulmonary-neuroendocrine-carcinomas-epnec-a-cognitive-debriefing-cd-interview-study?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2356-o16-poster-pavel-establishing-content-validity-of-patient-reported-outcome-pro-measures-in-extrapulmonary-neuroendocrine-carcinomas-epnec-a-cognitive-debriefing-cd-interview-study/file" length="439450" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2356-o16-poster-pavel-establishing-content-validity-of-patient-reported-outcome-pro-measures-in-extrapulmonary-neuroendocrine-carcinomas-epnec-a-cognitive-debriefing-cd-interview-study/file"
                fileSize="439450"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[O16 Poster] Pavel - Establishing content validity of patient reported outcome (PRO) measures in extrapulmonary neuroendocrine carcinomas (epNEC) A cognitive debriefing (CD) interview study</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2356-o16-poster-pavel-establishing-content-validity-of-patient-reported-outcome-pro-measures-in-extrapulmonary-neuroendocrine-carcinomas-epnec-a-cognitive-debriefing-cd-interview-study?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:55:17 -0500</pubDate>
       </item>
              <item>
           <title>[C20 Poster] Magoti - Outcomes of TARE as salvage liver directed therapy in patients with poor response to first line TAE TACE for neuroendocrine liver metastases</title>
           <link>https://nanets.net/abstracts-archive/2026/2355-c20-poster-magoti-outcomes-of-tare-as-salvage-liver-directed-therapy-in-patients-with-poor-response-to-first-line-tae-tace-for-neuroendocrine-liver-metastases?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2355-c20-poster-magoti-outcomes-of-tare-as-salvage-liver-directed-therapy-in-patients-with-poor-response-to-first-line-tae-tace-for-neuroendocrine-liver-metastases/file" length="2667623" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2355-c20-poster-magoti-outcomes-of-tare-as-salvage-liver-directed-therapy-in-patients-with-poor-response-to-first-line-tae-tace-for-neuroendocrine-liver-metastases/file"
                fileSize="2667623"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[C20 Poster] Magoti - Outcomes of TARE as salvage liver directed therapy in patients with poor response to first line TAE TACE for neuroendocrine liver metastases</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2355-c20-poster-magoti-outcomes-of-tare-as-salvage-liver-directed-therapy-in-patients-with-poor-response-to-first-line-tae-tace-for-neuroendocrine-liver-metastases?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:55:02 -0500</pubDate>
       </item>
              <item>
           <title>[C28 Poster] Maluccio - Longer Term Paltusotine Treatment in Patients With Carcinoid Syndrome Safety and Exploratory Efficacy Results From a 2 Year Open Label Extension Study</title>
           <link>https://nanets.net/abstracts-archive/2026/2354-c28-poster-maluccio-longer-term-paltusotine-treatment-in-patients-with-carcinoid-syndrome-safety-and-exploratory-efficacy-results-from-a-2-year-open-label-extension-study?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2354-c28-poster-maluccio-longer-term-paltusotine-treatment-in-patients-with-carcinoid-syndrome-safety-and-exploratory-efficacy-results-from-a-2-year-open-label-extension-study/file" length="374259" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2354-c28-poster-maluccio-longer-term-paltusotine-treatment-in-patients-with-carcinoid-syndrome-safety-and-exploratory-efficacy-results-from-a-2-year-open-label-extension-study/file"
                fileSize="374259"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[C28 Poster] Maluccio - Longer Term Paltusotine Treatment in Patients With Carcinoid Syndrome Safety and Exploratory Efficacy Results From a 2 Year Open Label Extension Study</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2354-c28-poster-maluccio-longer-term-paltusotine-treatment-in-patients-with-carcinoid-syndrome-safety-and-exploratory-efficacy-results-from-a-2-year-open-label-extension-study?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:54:42 -0500</pubDate>
       </item>
              <item>
           <title>[C22 Poster] Chang - Preoperative Somatostatin Receptor based Imaging Should be Routinely Performed in Neuroendocrine Tumors</title>
           <link>https://nanets.net/abstracts-archive/2026/2353-c22-poster-chang-preoperative-somatostatin-receptor-based-imaging-should-be-routinely-performed-in-neuroendocrine-tumors?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2353-c22-poster-chang-preoperative-somatostatin-receptor-based-imaging-should-be-routinely-performed-in-neuroendocrine-tumors/file" length="1594238" type="application/vnd.openxmlformats-officedocument.presentationml.presentation" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2353-c22-poster-chang-preoperative-somatostatin-receptor-based-imaging-should-be-routinely-performed-in-neuroendocrine-tumors/file"
                fileSize="1594238"
                type="application/vnd.openxmlformats-officedocument.presentationml.presentation"
                medium="document"
           />
           <media:title type="plain">[C22 Poster] Chang - Preoperative Somatostatin Receptor based Imaging Should be Routinely Performed in Neuroendocrine Tumors</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2353-c22-poster-chang-preoperative-somatostatin-receptor-based-imaging-should-be-routinely-performed-in-neuroendocrine-tumors?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:54:20 -0500</pubDate>
       </item>
              <item>
           <title>[P10 Poster] Soares - Characterizing the Epidemiology and Treatment Patterns of Carcinoid Syndrome Among Neuroendocrine Neoplasms in a Large Population Based Database</title>
           <link>https://nanets.net/abstracts-archive/2026/2352-p10-poster-soares-characterizing-the-epidemiology-and-treatment-patterns-of-carcinoid-syndrome-among-neuroendocrine-neoplasms-in-a-large-population-based-database?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2352-p10-poster-soares-characterizing-the-epidemiology-and-treatment-patterns-of-carcinoid-syndrome-among-neuroendocrine-neoplasms-in-a-large-population-based-database/file" length="374592" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2352-p10-poster-soares-characterizing-the-epidemiology-and-treatment-patterns-of-carcinoid-syndrome-among-neuroendocrine-neoplasms-in-a-large-population-based-database/file"
                fileSize="374592"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[P10 Poster] Soares - Characterizing the Epidemiology and Treatment Patterns of Carcinoid Syndrome Among Neuroendocrine Neoplasms in a Large Population Based Database</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2352-p10-poster-soares-characterizing-the-epidemiology-and-treatment-patterns-of-carcinoid-syndrome-among-neuroendocrine-neoplasms-in-a-large-population-based-database?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:53:59 -0500</pubDate>
       </item>
              <item>
           <title>[O10 Poster] Starr - Care Partner Experiences and Burden in Extrapulmonary Neuroendocrine Carcinoma Findings from the VOICE Survey</title>
           <link>https://nanets.net/abstracts-archive/2026/2351-o10-poster-starr-care-partner-experiences-and-burden-in-extrapulmonary-neuroendocrine-carcinoma-findings-from-the-voice-survey?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2351-o10-poster-starr-care-partner-experiences-and-burden-in-extrapulmonary-neuroendocrine-carcinoma-findings-from-the-voice-survey/file" length="200106" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2351-o10-poster-starr-care-partner-experiences-and-burden-in-extrapulmonary-neuroendocrine-carcinoma-findings-from-the-voice-survey/file"
                fileSize="200106"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[O10 Poster] Starr - Care Partner Experiences and Burden in Extrapulmonary Neuroendocrine Carcinoma Findings from the VOICE Survey</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2351-o10-poster-starr-care-partner-experiences-and-burden-in-extrapulmonary-neuroendocrine-carcinoma-findings-from-the-voice-survey?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:53:44 -0500</pubDate>
       </item>
              <item>
           <title>[O8 Poster] Francisco - Evaluation of Large Language Model Based Extraction of Neuroendocrine Neoplasm Variables from Pathology Reports</title>
           <link>https://nanets.net/abstracts-archive/2026/2350-o8-poster-francisco-evaluation-of-large-language-model-based-extraction-of-neuroendocrine-neoplasm-variables-from-pathology-reports?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2350-o8-poster-francisco-evaluation-of-large-language-model-based-extraction-of-neuroendocrine-neoplasm-variables-from-pathology-reports/file" length="1070230" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2350-o8-poster-francisco-evaluation-of-large-language-model-based-extraction-of-neuroendocrine-neoplasm-variables-from-pathology-reports/file"
                fileSize="1070230"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[O8 Poster] Francisco - Evaluation of Large Language Model Based Extraction of Neuroendocrine Neoplasm Variables from Pathology Reports</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2350-o8-poster-francisco-evaluation-of-large-language-model-based-extraction-of-neuroendocrine-neoplasm-variables-from-pathology-reports?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:53:31 -0500</pubDate>
       </item>
              <item>
           <title>[C40 Poster] Chauhan - Outcomes with first line obrixtamig plus standard of care in epNEC by DLL3 expression status Phase Ib DAREON® 7 study</title>
           <link>https://nanets.net/abstracts-archive/2026/2349-c40-poster-chauhan-outcomes-with-first-line-obrixtamig-plus-standard-of-care-in-epnec-by-dll3-expression-status-phase-ib-dareon-r-7-study?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2349-c40-poster-chauhan-outcomes-with-first-line-obrixtamig-plus-standard-of-care-in-epnec-by-dll3-expression-status-phase-ib-dareon-r-7-study/file" length="602987" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2349-c40-poster-chauhan-outcomes-with-first-line-obrixtamig-plus-standard-of-care-in-epnec-by-dll3-expression-status-phase-ib-dareon-r-7-study/file"
                fileSize="602987"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[C40 Poster] Chauhan - Outcomes with first line obrixtamig plus standard of care in epNEC by DLL3 expression status Phase Ib DAREON® 7 study</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2349-c40-poster-chauhan-outcomes-with-first-line-obrixtamig-plus-standard-of-care-in-epnec-by-dll3-expression-status-phase-ib-dareon-r-7-study?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:53:10 -0500</pubDate>
       </item>
              <item>
           <title>[T4 Poster] Ramage - Trial in Progress A Phase 2 Study of ONC206 (JZP3507) in Patients With Advanced Pheochromocytoma and Paraganglioma</title>
           <link>https://nanets.net/abstracts-archive/2026/2348-t4-poster-ramage-trial-in-progress-a-phase-2-study-of-onc206-jzp3507-in-patients-with-advanced-pheochromocytoma-and-paraganglioma?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2348-t4-poster-ramage-trial-in-progress-a-phase-2-study-of-onc206-jzp3507-in-patients-with-advanced-pheochromocytoma-and-paraganglioma/file" length="664592" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2348-t4-poster-ramage-trial-in-progress-a-phase-2-study-of-onc206-jzp3507-in-patients-with-advanced-pheochromocytoma-and-paraganglioma/file"
                fileSize="664592"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[T4 Poster] Ramage - Trial in Progress A Phase 2 Study of ONC206 (JZP3507) in Patients With Advanced Pheochromocytoma and Paraganglioma</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2348-t4-poster-ramage-trial-in-progress-a-phase-2-study-of-onc206-jzp3507-in-patients-with-advanced-pheochromocytoma-and-paraganglioma?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:52:51 -0500</pubDate>
       </item>
              <item>
           <title>[B10 Poster] Abbu - Tumor Microenvironment Remodeling Mediates Resistance to 177Lu DOTATATE in Metastatic Well Differentiated Neuroendocrine Tumors</title>
           <link>https://nanets.net/abstracts-archive/2026/2347-b10-poster-abbu-tumor-microenvironment-remodeling-mediates-resistance-to-177lu-dotatate-in-metastatic-well-differentiated-neuroendocrine-tumors?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2347-b10-poster-abbu-tumor-microenvironment-remodeling-mediates-resistance-to-177lu-dotatate-in-metastatic-well-differentiated-neuroendocrine-tumors/file" length="18869105" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2347-b10-poster-abbu-tumor-microenvironment-remodeling-mediates-resistance-to-177lu-dotatate-in-metastatic-well-differentiated-neuroendocrine-tumors/file"
                fileSize="18869105"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[B10 Poster] Abbu - Tumor Microenvironment Remodeling Mediates Resistance to 177Lu DOTATATE in Metastatic Well Differentiated Neuroendocrine Tumors</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2347-b10-poster-abbu-tumor-microenvironment-remodeling-mediates-resistance-to-177lu-dotatate-in-metastatic-well-differentiated-neuroendocrine-tumors?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:52:38 -0500</pubDate>
       </item>
              <item>
           <title>[O2 Poster] Chauhan - Real World Patient Journey in Extrapulmonary Neuroendocrine Carcinoma (epNEC) Perspectives of Patients from the VOICE Study</title>
           <link>https://nanets.net/abstracts-archive/2026/2346-o2-poster-chauhan-real-world-patient-journey-in-extrapulmonary-neuroendocrine-carcinoma-epnec-perspectives-of-patients-from-the-voice-study?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2346-o2-poster-chauhan-real-world-patient-journey-in-extrapulmonary-neuroendocrine-carcinoma-epnec-perspectives-of-patients-from-the-voice-study/file" length="219904" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2346-o2-poster-chauhan-real-world-patient-journey-in-extrapulmonary-neuroendocrine-carcinoma-epnec-perspectives-of-patients-from-the-voice-study/file"
                fileSize="219904"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[O2 Poster] Chauhan - Real World Patient Journey in Extrapulmonary Neuroendocrine Carcinoma (epNEC) Perspectives of Patients from the VOICE Study</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2346-o2-poster-chauhan-real-world-patient-journey-in-extrapulmonary-neuroendocrine-carcinoma-epnec-perspectives-of-patients-from-the-voice-study?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:52:20 -0500</pubDate>
       </item>
              <item>
           <title>[O9 Poster] Starr - Real World Management of Extrapulmonary Neuroendocrine Carcinoma (epNEC) from the Perspective of Healthcare Providers in the VOICE Study</title>
           <link>https://nanets.net/abstracts-archive/2026/2345-o9-poster-starr-real-world-management-of-extrapulmonary-neuroendocrine-carcinoma-epnec-from-the-perspective-of-healthcare-providers-in-the-voice-study?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2345-o9-poster-starr-real-world-management-of-extrapulmonary-neuroendocrine-carcinoma-epnec-from-the-perspective-of-healthcare-providers-in-the-voice-study/file" length="213264" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2345-o9-poster-starr-real-world-management-of-extrapulmonary-neuroendocrine-carcinoma-epnec-from-the-perspective-of-healthcare-providers-in-the-voice-study/file"
                fileSize="213264"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[O9 Poster] Starr - Real World Management of Extrapulmonary Neuroendocrine Carcinoma (epNEC) from the Perspective of Healthcare Providers in the VOICE Study</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2345-o9-poster-starr-real-world-management-of-extrapulmonary-neuroendocrine-carcinoma-epnec-from-the-perspective-of-healthcare-providers-in-the-voice-study?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:52:04 -0500</pubDate>
       </item>
              <item>
           <title>[C39 Poster] Shah - Real World Evidence of Response to 177Lu DOTATATE PRRT Based on Primary and Metastatic Sites in Patients with Neuroendocrine Tumor</title>
           <link>https://nanets.net/abstracts-archive/2026/2344-c39-poster-shah-real-world-evidence-of-response-to-177lu-dotatate-prrt-based-on-primary-and-metastatic-sites-in-patients-with-neuroendocrine-tumor?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2344-c39-poster-shah-real-world-evidence-of-response-to-177lu-dotatate-prrt-based-on-primary-and-metastatic-sites-in-patients-with-neuroendocrine-tumor/file" length="264950" type="application/vnd.openxmlformats-officedocument.presentationml.presentation" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2344-c39-poster-shah-real-world-evidence-of-response-to-177lu-dotatate-prrt-based-on-primary-and-metastatic-sites-in-patients-with-neuroendocrine-tumor/file"
                fileSize="264950"
                type="application/vnd.openxmlformats-officedocument.presentationml.presentation"
                medium="document"
           />
           <media:title type="plain">[C39 Poster] Shah - Real World Evidence of Response to 177Lu DOTATATE PRRT Based on Primary and Metastatic Sites in Patients with Neuroendocrine Tumor</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2344-c39-poster-shah-real-world-evidence-of-response-to-177lu-dotatate-prrt-based-on-primary-and-metastatic-sites-in-patients-with-neuroendocrine-tumor?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:51:52 -0500</pubDate>
       </item>
              <item>
           <title>[C3 Poster] Islam - Stage Independent Prognostic Value of TP53 and DAXX ATRX in Pancreatic Malignant Carcinoid and Neuroendocrine Carcinoma</title>
           <link>https://nanets.net/abstracts-archive/2026/2343-c3-poster-islam-stage-independent-prognostic-value-of-tp53-and-daxx-atrx-in-pancreatic-malignant-carcinoid-and-neuroendocrine-carcinoma?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2343-c3-poster-islam-stage-independent-prognostic-value-of-tp53-and-daxx-atrx-in-pancreatic-malignant-carcinoid-and-neuroendocrine-carcinoma/file" length="2142716" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2343-c3-poster-islam-stage-independent-prognostic-value-of-tp53-and-daxx-atrx-in-pancreatic-malignant-carcinoid-and-neuroendocrine-carcinoma/file"
                fileSize="2142716"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[C3 Poster] Islam - Stage Independent Prognostic Value of TP53 and DAXX ATRX in Pancreatic Malignant Carcinoid and Neuroendocrine Carcinoma</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2343-c3-poster-islam-stage-independent-prognostic-value-of-tp53-and-daxx-atrx-in-pancreatic-malignant-carcinoid-and-neuroendocrine-carcinoma?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:51:30 -0500</pubDate>
       </item>
              <item>
           <title>[T6 Poster] Halfdanarson - DAREON® NEC 1 Phase III trial of first line obrixtamig plus carboplatin and etoposide (SoC) vs SoC in patients with DLL3 positive epNEC</title>
           <link>https://nanets.net/abstracts-archive/2026/2342-t6-poster-halfdanarson-dareon-r-nec-1-phase-iii-trial-of-first-line-obrixtamig-plus-carboplatin-and-etoposide-soc-vs-soc-in-patients-with-dll3-positive-epnec?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2342-t6-poster-halfdanarson-dareon-r-nec-1-phase-iii-trial-of-first-line-obrixtamig-plus-carboplatin-and-etoposide-soc-vs-soc-in-patients-with-dll3-positive-epnec/file" length="809068" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2342-t6-poster-halfdanarson-dareon-r-nec-1-phase-iii-trial-of-first-line-obrixtamig-plus-carboplatin-and-etoposide-soc-vs-soc-in-patients-with-dll3-positive-epnec/file"
                fileSize="809068"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[T6 Poster] Halfdanarson - DAREON® NEC 1 Phase III trial of first line obrixtamig plus carboplatin and etoposide (SoC) vs SoC in patients with DLL3 positive epNEC</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2342-t6-poster-halfdanarson-dareon-r-nec-1-phase-iii-trial-of-first-line-obrixtamig-plus-carboplatin-and-etoposide-soc-vs-soc-in-patients-with-dll3-positive-epnec?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:51:12 -0500</pubDate>
       </item>
              <item>
           <title>[C8 Poster] Toliver - Patterns of Metastases and Outcomes in Patients with Pancreatic Neuroendocrine Tumors</title>
           <link>https://nanets.net/abstracts-archive/2026/2341-c8-poster-toliver-patterns-of-metastases-and-outcomes-in-patients-with-pancreatic-neuroendocrine-tumors?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2341-c8-poster-toliver-patterns-of-metastases-and-outcomes-in-patients-with-pancreatic-neuroendocrine-tumors/file" length="245251" type="application/vnd.openxmlformats-officedocument.presentationml.presentation" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2341-c8-poster-toliver-patterns-of-metastases-and-outcomes-in-patients-with-pancreatic-neuroendocrine-tumors/file"
                fileSize="245251"
                type="application/vnd.openxmlformats-officedocument.presentationml.presentation"
                medium="document"
           />
           <media:title type="plain">[C8 Poster] Toliver - Patterns of Metastases and Outcomes in Patients with Pancreatic Neuroendocrine Tumors</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2341-c8-poster-toliver-patterns-of-metastases-and-outcomes-in-patients-with-pancreatic-neuroendocrine-tumors?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:50:54 -0500</pubDate>
       </item>
              <item>
           <title>[B12 Poster] Prabhu - Allosteric ClpP agonist JZP3507 (formerly ONC206) alters mitochondrial metabolism, stress response and chromatin accessibility to elicit apoptosis in pheochromocytoma</title>
           <link>https://nanets.net/abstracts-archive/2026/2340-b12-poster-prabhu-allosteric-clpp-agonist-jzp3507-formerly-onc206-alters-mitochondrial-metabolism-stress-response-and-chromatin-accessibility-to-elicit-apoptosis-in-pheochromocytoma?format=html</link>
           <enclosure url="https://nanets.net/abstracts-archive/2026/2340-b12-poster-prabhu-allosteric-clpp-agonist-jzp3507-formerly-onc206-alters-mitochondrial-metabolism-stress-response-and-chromatin-accessibility-to-elicit-apoptosis-in-pheochromocytoma/file" length="2051673" type="application/pdf" />
           <media:content
                url="https://nanets.net/abstracts-archive/2026/2340-b12-poster-prabhu-allosteric-clpp-agonist-jzp3507-formerly-onc206-alters-mitochondrial-metabolism-stress-response-and-chromatin-accessibility-to-elicit-apoptosis-in-pheochromocytoma/file"
                fileSize="2051673"
                type="application/pdf"
                medium="document"
           />
           <media:title type="plain">[B12 Poster] Prabhu - Allosteric ClpP agonist JZP3507 (formerly ONC206) alters mitochondrial metabolism, stress response and chromatin accessibility to elicit apoptosis in pheochromocytoma</media:title>
           <media:description type="html"><![CDATA[]]></media:description>
                      <guid isPermaLink="true">https://nanets.net/abstracts-archive/2026/2340-b12-poster-prabhu-allosteric-clpp-agonist-jzp3507-formerly-onc206-alters-mitochondrial-metabolism-stress-response-and-chromatin-accessibility-to-elicit-apoptosis-in-pheochromocytoma?format=html</guid>
           <description><![CDATA[]]></description>
           <author>staff@nanets.net (NANETS Staff)</author>
           <category>2026</category>
           <pubDate>Wed, 04 Nov 2026 23:50:30 -0500</pubDate>
       </item>
          </channel>
</rss>